AT9283, originally identified as a multi-target kinase inhibitor against aurora A, Aurora B, JAK3, JAK2, and Abl, has been reported to be effective drug against leukemia cells, myeloproliferative diseases and various solid cancer cell lines [29, 33, 51, 52]. Here, JAK3 is linked to leukemia.